Literature DB >> 15049018

Technical aspects in cerebrospinal irradiation.

Valérie Bernier1.   

Abstract

BACKGROUND: Craniospinal irradiation (CSI) is commonly used for medulloblastoma patients and some others; for example, those with ependymoma. It is a complex technique where accuracy of field placement and choice of irradiation source and energy can play a major role in determining success or failure. PROCEDURE: A literature review of the techniques used and reported by treatment centers was undertaken.
RESULTS: Great variability was found in methods and practices. This is striking because many hospitals treat fewer than five patients per year.
CONCLUSION: Standardized techniques with strict central review for quality control before therapy is initiated should become the norm. Standardization is especially important when clinical trials are planned. Valid outcome data depend on CSI uniformity. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2004        PMID: 15049018     DOI: 10.1002/pbc.10468

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  3 in total

Review 1.  Growth hormone treatment and risk of malignancy.

Authors:  Hyun-Wook Chae; Duk-Hee Kim; Ho-Seong Kim
Journal:  Korean J Pediatr       Date:  2015-02-28

2.  Outcome and prognostic factors following palliative craniospinal irradiation for leptomeningeal carcinomatosis.

Authors:  Rami A El Shafie; Karina Böhm; Dorothea Weber; Kristin Lang; Fabian Schlaich; Sebastian Adeberg; Angela Paul; Matthias F Haefner; Sonja Katayama; Florian Sterzing; Juliane Hörner-Rieber; Sarah Löw; Klaus Herfarth; Jürgen Debus; Stefan Rieken; Denise Bernhardt
Journal:  Cancer Manag Res       Date:  2019-01-17       Impact factor: 3.989

3.  Implementation of a DVH Registry to provide constraints and continuous quality monitoring for pediatric CSI treatment planning.

Authors:  Esteban Sepulveda; Haley Patrick; Carolyn R Freeman; John Kildea
Journal:  J Appl Clin Med Phys       Date:  2020-12-14       Impact factor: 2.102

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.